Related Experiment Video
Updated: Jul 11, 2025
07:29
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
10.8K
Bronchial embolisation for infected pulmonary artery pseudoaneurysms causing haemoptysis
1Department of Interventional Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441000, China.
Clinical Radiology
|November 10, 2023
Summary
Bronchial artery embolisation (BAE) effectively controls haemoptysis in patients with infected pulmonary artery pseudoaneurysms (PAPs). This interventional radiology technique demonstrated high success rates in a recent study, offering a valuable treatment option.
Area of Science:
- Interventional Radiology
- Pulmonary Medicine
- Vascular Imaging
Background:
- Infected pulmonary artery pseudoaneurysms (PAPs) can cause life-threatening haemoptysis.
- Computed tomography angiography (CTA) is crucial for diagnosing PAPs and identifying bleeding sources.
- Tuberculosis is a significant underlying cause of PAPs.
Purpose of the Study:
- To evaluate the efficacy of bronchial artery embolisation (BAE) in controlling haemoptysis.
- To assess the technical and clinical success of BAE for infected PAPs.
Main Methods:
- Retrospective review of patients undergoing BAE for haemoptysis due to infectious PAPs.
- Data collection included patient demographics, underlying pathology, imaging findings, and procedural outcomes.
- Systemic angiography was used to visualize PAPs and guide embolisation.
Main Results:
- Seventeen PAPs in 16 patients were treated, with tuberculosis being the most common cause.
- CTA failed to identify the source pulmonary artery in most cases (88.2%).
- BAE achieved technical and clinical success rates of 87.5%, with two recurrences successfully managed.
Conclusions:
- Bronchial artery embolisation is a valuable technique for managing haemoptysis from infected PAPs.
- The small size of pulmonary arteries supplying PAPs may contribute to their development.
- BAE offers a promising interventional approach for this challenging condition.
Related Concept Videos
01:29Pulmonary Embolism I: Introduction
7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
01:27Pneumothorax-II
168
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
168
01:27Pulmonary Embolism III: Nursing Management
15
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
15
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
172
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
177
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177